Your browser doesn't support javascript.
loading
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial.
West, Howard Jack; McCleland, Mark; Cappuzzo, Federico; Reck, Martin; Mok, Tony Sk; Jotte, Robert M; Nishio, Makoto; Kim, Eugene; Morris, Stefanie; Zou, Wei; Shames, David; Das Thakur, Meghna; Shankar, Geetha; Socinski, Mark A.
Afiliación
  • West HJ; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA jackwestmd@gmail.com.
  • McCleland M; Genentech Inc, South San Francisco, California, USA.
  • Cappuzzo F; Oncology Department, Istituto Nazionale Tumori "Regina Elena", Rome, Italy.
  • Reck M; Department of Thoracic Oncology, LungenClinic Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany.
  • Mok TS; State Key Laboratory of Translational Oncology, Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
  • Jotte RM; Department of Medical Oncology, Rocky Mountain Cancer Centers, Denver, Colorado, USA.
  • Nishio M; US Oncology, Houston, Texas, USA.
  • Kim E; Thoracic Medical Oncology Department, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Morris S; Genentech Inc, South San Francisco, California, USA.
  • Zou W; Product Development Medical Affairs, F Hoffmann-La Roche Ltd, Basel, Switzerland.
  • Shames D; Genentech Inc, South San Francisco, California, USA.
  • Das Thakur M; Genentech Inc, South San Francisco, California, USA.
  • Shankar G; Genentech Inc, South San Francisco, California, USA.
  • Socinski MA; Genentech Inc, South San Francisco, California, USA.
J Immunother Cancer ; 10(2)2022 02.
Article en En | MEDLINE | ID: mdl-35190375
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteína p53 Supresora de Tumor / Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Bevacizumab / Proteína 1 Asociada A ECH Tipo Kelch / Quinasas de la Proteína-Quinasa Activada por el AMP / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Proteína p53 Supresora de Tumor / Carcinoma de Pulmón de Células no Pequeñas / Anticuerpos Monoclonales Humanizados / Bevacizumab / Proteína 1 Asociada A ECH Tipo Kelch / Quinasas de la Proteína-Quinasa Activada por el AMP / Neoplasias Pulmonares Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Middle aged Idioma: En Revista: J Immunother Cancer Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos